ARTICLE | Clinical News

Dendreon gains on Provenge data

October 7, 2008 1:35 AM UTC

Dendreon (NASDAQ:DNDN) gained $1.73 (33%) to $6.93 on Monday after an interim analysis triggered by 164 deaths in the Phase III IMPACT trial (D9902B) in 512 men with metastatic androgen-independent prostate cancer (AIPC) showed Provenge reduced the risk of death by 20%. The trial's IDMC recommended the double-blind, placebo-controlled, North American study continue to its final analysis, which will be triggered by 304 deaths. The company expects to report final data in mid-2009. ...